135 related articles for article (PubMed ID: 31456522)
1. The Application of the RNA Interference Technologies for KRAS: Current Status, Future Perspective and Associated Challenges.
Shao YT; Ma L; Zhang TH; Xu TR; Ye YC; Liu Y
Curr Top Med Chem; 2019; 19(23):2143-2157. PubMed ID: 31456522
[TBL] [Abstract][Full Text] [Related]
2. KRAS: A Promising Therapeutic Target for Cancer Treatment.
Wu HZ; Xiao JQ; Xiao SS; Cheng Y
Curr Top Med Chem; 2019; 19(23):2081-2097. PubMed ID: 31486755
[TBL] [Abstract][Full Text] [Related]
3. Targeting Mutant KRAS for Anticancer Therapy.
Chen F; Alphonse MP; Liu Y; Liu Q
Curr Top Med Chem; 2019; 19(23):2098-2113. PubMed ID: 31475898
[TBL] [Abstract][Full Text] [Related]
4. Selective targeting of the oncogenic
Gao Q; Ouyang W; Kang B; Han X; Xiong Y; Ding R; Li Y; Wang F; Huang L; Chen L; Wang D; Dong X; Zhang Z; Li Y; Ze B; Hou Y; Yang H; Ma Y; Gu Y; Chao CC
Theranostics; 2020; 10(11):5137-5153. PubMed ID: 32308773
[No Abstract] [Full Text] [Related]
5. A CRISPR-Cas13a system for efficient and specific therapeutic targeting of mutant KRAS for pancreatic cancer treatment.
Zhao X; Liu L; Lang J; Cheng K; Wang Y; Li X; Shi J; Wang Y; Nie G
Cancer Lett; 2018 Sep; 431():171-181. PubMed ID: 29870774
[TBL] [Abstract][Full Text] [Related]
6. Drug Discovery by Targeting Mutant KRAS.
Ye N
Curr Top Med Chem; 2019; 19(23):2079-2080. PubMed ID: 31762422
[No Abstract] [Full Text] [Related]
7. Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1.
Barbie DA; Tamayo P; Boehm JS; Kim SY; Moody SE; Dunn IF; Schinzel AC; Sandy P; Meylan E; Scholl C; Fröhling S; Chan EM; Sos ML; Michel K; Mermel C; Silver SJ; Weir BA; Reiling JH; Sheng Q; Gupta PB; Wadlow RC; Le H; Hoersch S; Wittner BS; Ramaswamy S; Livingston DM; Sabatini DM; Meyerson M; Thomas RK; Lander ES; Mesirov JP; Root DE; Gilliland DG; Jacks T; Hahn WC
Nature; 2009 Nov; 462(7269):108-12. PubMed ID: 19847166
[TBL] [Abstract][Full Text] [Related]
8. Drug Combinatorial Therapies for the Treatment of KRAS Mutated Lung Cancers.
He H; Xu C; Cheng Z; Qian X; Zheng L
Curr Top Med Chem; 2019; 19(23):2128-2142. PubMed ID: 31475900
[TBL] [Abstract][Full Text] [Related]
9. Kirsten Ras* oncogene: significance of its discovery in human cancer research.
Tsuchida N; Murugan AK; Grieco M
Oncotarget; 2016 Jul; 7(29):46717-46733. PubMed ID: 27102293
[TBL] [Abstract][Full Text] [Related]
10. KRAS as a Therapeutic Target.
McCormick F
Clin Cancer Res; 2015 Apr; 21(8):1797-801. PubMed ID: 25878360
[TBL] [Abstract][Full Text] [Related]
11. Specific and Efficient Regression of Cancers Harboring KRAS Mutation by Targeted RNA Replacement.
Kim SJ; Kim JH; Yang B; Jeong JS; Lee SW
Mol Ther; 2017 Feb; 25(2):356-367. PubMed ID: 28153088
[TBL] [Abstract][Full Text] [Related]
12. Overview of Current Immunotherapies Targeting Mutated KRAS Cancers.
Hoo WPY; Siak PY; In LLA
Curr Top Med Chem; 2019; 19(23):2158-2175. PubMed ID: 31483231
[TBL] [Abstract][Full Text] [Related]
13. Nucleic Acid-Based Approaches to Tackle KRAS Mutant Cancers.
Kim J
Int J Mol Sci; 2023 Nov; 24(23):. PubMed ID: 38069255
[TBL] [Abstract][Full Text] [Related]
14. KRAS Alleles: The Devil Is in the Detail.
Haigis KM
Trends Cancer; 2017 Oct; 3(10):686-697. PubMed ID: 28958387
[TBL] [Abstract][Full Text] [Related]
15. Lactate dehydrogenase B is required for the growth of KRAS-dependent lung adenocarcinomas.
McCleland ML; Adler AS; Deming L; Cosino E; Lee L; Blackwood EM; Solon M; Tao J; Li L; Shames D; Jackson E; Forrest WF; Firestein R
Clin Cancer Res; 2013 Feb; 19(4):773-84. PubMed ID: 23224736
[TBL] [Abstract][Full Text] [Related]
16. Ras and exosome signaling.
Sexton RE; Mpilla G; Kim S; Philip PA; Azmi AS
Semin Cancer Biol; 2019 Feb; 54():131-137. PubMed ID: 30769101
[TBL] [Abstract][Full Text] [Related]
17. Kirsten Rat Sarcoma Viral Oncogene Homologue (KRAS) Mutations in the Occurrence and Treatment of Pancreatic Cancer.
Zhu Z; Xiao S; Hao H; Hou Q; Fu X
Curr Top Med Chem; 2019; 19(23):2176-2186. PubMed ID: 31456520
[TBL] [Abstract][Full Text] [Related]
18. Enhanced dependency of KRAS-mutant colorectal cancer cells on RAD51-dependent homologous recombination repair identified from genetic interactions in Saccharomyces cerevisiae.
Kalimutho M; Bain AL; Mukherjee B; Nag P; Nanayakkara DM; Harten SK; Harris JL; Subramanian GN; Sinha D; Shirasawa S; Srihari S; Burma S; Khanna KK
Mol Oncol; 2017 May; 11(5):470-490. PubMed ID: 28173629
[TBL] [Abstract][Full Text] [Related]
19. Heterogeneity and mutation in KRAS and associated oncogenes: evaluating the potential for the evolution of resistance to targeting of KRAS G12C.
Cannataro VL; Gaffney SG; Stender C; Zhao ZM; Philips M; Greenstein AE; Townsend JP
Oncogene; 2018 May; 37(18):2444-2455. PubMed ID: 29453361
[TBL] [Abstract][Full Text] [Related]
20. Synthetic Lethal Vulnerabilities in
Aguirre AJ; Hahn WC
Cold Spring Harb Perspect Med; 2018 Aug; 8(8):. PubMed ID: 29101114
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
